New effective strategy: Oncolytic Virus and its application in cancer therapy
- Oncolytic virus development history and successful case
- Classification and characteristics of oncolytic virus
- MoA of oncolytic virus in treating tumor
- Key bottleneck limiting the therapeutic application of oncolytic virus
- Global & China R&D landscape of oncolytic virus
- Guest speaker：An EU innovative biotech shares its development and breakthrough in cancer therapy and assets available for China market
Event details
|
DATE Thursday Sep 9th, 2021 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 - 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Sep 8th, 2021 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor Guest speaker REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:30 | – Oncolytic virus development history and successful case – Classification and characteristics of oncolytic virus – MoA of oncolytic virus treating tumor – Key bottleneck limiting the therapeutic application of oncolytic virus – Global & China R&D landscape of oncolytic virus |
by Dr Hank Wang (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introductions | by Lingling Cao (English) |
| CET 10:35 - 10:55 | Guest speaker：An EU innovative biotech shares its development and breakthrough in cancer therapy and assets available for China market | by Guest speaker (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |